Artivion's management optimizes capital structure for a new phase of profitable growth. Strong conviction in business outlook, recent financial performance and clinical data readouts expected to deliver significant shareholder value.
Artivion's reinvestment has not significantly improved sales, resulting in a 52% decline in stock over the past five years. The market perspective shows skepticism, implying Artivion may not have substantial growth potential.
アーティヴィオンに関するコメント
In reaction to earnings/guidance:
• $カランプ(CAMP.US)$ +0.6%
Other news:
• $カノ・ヘルス(CANO.US)$ +6.1% ( $ヒューマナ(HUM.US)$ in the running to acquire CANO according to WSJ)
• $コーセプト セラピューティクス(CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL フィナンシャル ホールディングス(LPLA.US)$ +4.1% (reports monthly activity for August)
• $デンツプライ シロナ(XRAY.US)$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US)$ +2.9% (tr...
まだコメントはありません